Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Use multiple ‘targeted’ drugs on tumors, say researchers
The switches are formed by molecules called receptor tyrosine kinases (RTKs) that often are mutated and hyperactive in cancer cells. Since a number of kinase-blocking drugs are already
The switches are formed by molecules called receptor tyrosine kinases (RTKs) that often are mutated and hyperactive in cancer cells. Since a number of kinase-blocking drugs are already
The Texas-based biopharmaceutical company said that its investigational new drug (IND) application for the US study of Proellex became effective on September 10, 2007. The first study conducted
The Phase I trial, which evaluated 66 obese and mildly obese volunteers, demonstrated clinically relevant reductions in body fat, energy intake and waist circumference. V24343 was generally well
Under the terms of the deal, Best Medical will purchase Nomos Corporation assets, including stock of Nomos subsidiaries, Nomos GmbH and Nomos China USA. The purchase price is
The company is planning to present the results evaluating HE3286 at the 2nd International Congress on Immune-Mediated Diseases being held in Moscow, Russia. The company is also presenting
The randomized trial enrolls 300 patients and expects to complete over a 12 to 16-month period. Depending on the rate of progression, an interim analysis is targeted for
The Europe-based study, designed to assess the safety and pharmacokinetics of Xoma 052, will enroll up to 36 subjects with type 2 diabetes and includes disease-specific outcome measurements.
The acquisition positions Walgreens as one of the largest home infusion therapy providers in US and expands its respiratory therapy and durable medical equipment services. Option Care services
Mr Fogelman has more than 30 years of financial and accounting experience and has previously worked with International Aluminum Corporation. CytRx president and CEO Steven Kriegsman said: “Mitch
The court has ordered Ranbaxy to delay launching its product until expiration of the patent in July 2016. Ranbaxy may seek to appeal this decision. However, the court